Gabrielli M, Vivanco M, Hepp J, Martínez J, Pérez R, Guerra J, Arrese M, Figueroa E, Soza A, Yáñes R, Humeres R, Rios H, Palacios J M, Zapata R, Sanhueza E, Contreras J, Rencoret G, Rossi R, Jarufe N
Liver transplantation Program, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile.
Transplant Proc. 2010 Jan-Feb;42(1):299-301. doi: 10.1016/j.transproceed.2009.11.034.
Hepatocellular carcinoma (HCC) is the most common malignant tumor of the liver. Liver transplantation is the best treatment for HCC; it improves survival, cures cirrhosis, and abolishes local recurrence. We describe the outcomes of patients with HCC who underwent liver transplantation in two liver transplantation centers in Chile.
This study is a clinical series elaborated from the liver transplantation database of Pontificia Universidad Católica and Clínica Alemana between 1993 and 2009. The survival of patients was calculated using the Kaplan-Meier survival analysis. The significant alpha level was defined as <.05.
From 250 liver transplantations performed in this period, 29 were due to HCC. At the end of the study, 25 patients (86%) were alive. The mean recurrence-free survival was 30 months (range 5 months to 8 years). The 5-year survival for patients transplanted for HCC was >80%; however, the 5-year overall survival of patients who exceeded the Milan criteria in the explants was 66%. There was no difference in overall survival between patients transplanted for HCC versus other diagnosis (P = .548).
This series confirmed that liver transplantation is a good treatment for patients with HCC within the Milan criteria.
肝细胞癌（HCC）是最常见的肝脏恶性肿瘤。肝移植是治疗HCC的最佳方法；它可提高生存率、治愈肝硬化并消除局部复发。我们描述了在智利两个肝移植中心接受肝移植的HCC患者的治疗结果。
本研究是一项临床系列研究，根据1993年至2009年间天主教大学和德国诊所的肝移植数据库制定。使用Kaplan-Meier生存分析计算患者的生存率。显著α水平定义为<.05。
在此期间进行的250例肝移植中，29例是由于HCC。在研究结束时，25例患者（86%）存活。平均无复发生存期为30个月（范围为5个月至8年）。因HCC接受移植的患者5年生存率>80%；然而，移植肝中超过米兰标准的患者5年总生存率为66%。因HCC接受移植的患者与其他诊断患者的总生存率无差异（P =.548）。
本系列研究证实，肝移植是米兰标准内HCC患者的良好治疗方法。
